World Immuno-Oncology Diagnostics Markets, 2022-2026: Shifting Role of Diagnostics, Multiplexing and Foundation One, The Disruption Dynamic, The Race for Biomarkers, The Next Five Years

News provided by

Dec 13, 2021, 06:15 ET

DUBLIN, Dec. 13, 2021 /PRNewswire/ -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates, 2022 - 2026" report has been added to ResearchAndMarkets.com's offering.

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created and its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success but diagnostics, especially biomarkers, are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines?

Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

Market Trends

Factors Driving Growth

Outcome potential
Companion Diagnostics
Funding
Technology Environment
Target Solutions

Factors Limiting Growth

Complex Role of Diagnostics
Clinical Trials Role
Protocols

Diagnostic Technology Development

Combinations - Issues and Complexity
Shifting Role of Diagnostics
Multiplexing and Foundation One
The Disruption Dynamic
The Race for Biomarkers
The Next Five Years

Cancer Immuno-Oncology Diagnostics Recent Developments

Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
Qiagen, OncXerna Close Companion Dx Development Deal
Natera Test to Guide Therapy for Bladder Cancer
Veracyte Halio Acquisition to Boost Immuno-oncology Activity
Freenome Eyes New Dx Possibilities
Oncocyte Data has Potential as Immunotherapy Response Predictor
OncoDNA use HalioDx to Expand into North America
Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay .
Qiagen Expands Immuno-Oncology Portfolio
Immune Profiling System Redirected to Fight COVID-19
IncellDx Awarded PD-L1 Detection Patent
FDA Approves CDx for Trastuzumab
Promega Nabs CE Mark for Microsatellite Instability IVD
ArcherDx partners with AstraZeneca for Immuno-Oncology
Germline Results Guides Precision Therapy
Agilent PD-L1 Assay Gets FDA Approval
Bayer, OrigiMed Form Companion Diagnostic Development Alliance
Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
Biocare Medical Launches 7 Novel IVD Antibodies
Oncocyte to Acquire Insight Genetics for $12M
Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
Generex to Merge with NuGenerex Immuno-Oncology
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies
Hematogenix Launches FDA Approved Immuno-oncology Test for Triple Negative Breast Cancer
Icon Acquires MolecularMD

Companies Mentioned

10x Genomics, Inc.
Abbott Diagnostics
AccuraGen Inc.
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience, Inc
Agilent/Dako
Anchor Dx
ANGLE plc
ApoCell, Inc.
ARUP Laboratories
Asuragen
AVIVA Biosciences
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocartis
Biocept, Inc.
Biodesix Inc.
BioFluidica
BioGenex
BioIVT
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Bio-Reference Laboratories
Bio-Techne
Bioview
Bolidics
Boreal Genomics
Bristol-Myers Squibb
Burning Rock
Cancer Genetics
Caris Molecular Diagnostics
Castle Biosciences, Inc.
CellMax Life
Cepheid (Danaher)
Charles River Laboratories
Chronix Biomedical
Circulogene
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp.
CytoTrack
Datar Cancer Genetics Limited
Diagnologix LLC
Diasorin S.p.A.
Enzo Biochem
Epic Sciences
Epigenomics AG
Eurofins Scientific
Exosome Diagnostics
Exosome Sciences
Fabric Genomics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
FUJIFILM Wako Diagnostics
GeneFirst Ltd.
Genetron Holdings
GenomOncology
GILUPI Nanomedizin
Grail, Inc.
Guardant Health
HalioDx
HansaBiomed
HeiScreen
Helomics
Horizon Discovery
HTG Molecular Diagnostics
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invitae Corporation
Invivogen
Invivoscribe
Janssen Diagnostics
MDNA Life SCIENCES, Inc.
MDx Health
Menarini Silicon Biosystems
Millipore Sigma
Miltenyi Biotec
MIODx
miR Scientific
Molecular MD
MyCartis
Myriad Genetics/Myriad RBM
NantHealth, Inc.
Natera
NeoGenomics
New Oncology
NGeneBio
Novogene Bioinformatics Technology Co., Ltd.
Oncocyte
OncoDNA
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
Panagene
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
PrecisionMed
Promega
Qiagen Gmbh
Rarecells SAS
RareCyte
Roche Molecular Diagnostics
Screencell
Sense Biodetection
Serametrix
Siemens Healthineers
Silicon Biosystems
simfo GmbH
Singlera Genomics Inc.
Singulomics
SkylineDx
Stratos Genomics
Sysmex Inostics
Tempus Labs, Inc.
Thermo Fisher Scientific Inc.
Thrive Earlier Detection
Todos Medical
Trovagene
Volition
Vortex Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/on1y78

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets